These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 39107717)

  • 1. Chimeric antigen receptor-T cells targeting epithelial cell adhesion molecule antigens are effective in the treatment of colorectal cancer.
    Zeng S; Jin N; Yu B; Ren Q; Yan Z; Fu S
    BMC Gastroenterol; 2024 Aug; 24(1):249. PubMed ID: 39107717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical Evaluation of Chimeric Antigen Receptor-Modified T Cells Specific to Epithelial Cell Adhesion Molecule for Treating Colorectal Cancer.
    Zhang BL; Li D; Gong YL; Huang Y; Qin DY; Jiang L; Liang X; Yang X; Gou HF; Wang YS; Wei YQ; Wang W
    Hum Gene Ther; 2019 Apr; 30(4):402-412. PubMed ID: 30693795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination Therapy with EpCAM-CAR-NK-92 Cells and Regorafenib against Human Colorectal Cancer Models.
    Zhang Q; Zhang H; Ding J; Liu H; Li H; Li H; Lu M; Miao Y; Li L; Zheng J
    J Immunol Res; 2018; 2018():4263520. PubMed ID: 30410941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic effect of dual CAR-T targeting PDL1 and MUC16 antigens on ovarian cancer cells in mice.
    Li T; Wang J
    BMC Cancer; 2020 Jul; 20(1):678. PubMed ID: 32689954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intraperitoneal immunotherapy with T cells stably and transiently expressing anti-EpCAM CAR in xenograft models of peritoneal carcinomatosis.
    Ang WX; Li Z; Chi Z; Du SH; Chen C; Tay JC; Toh HC; Connolly JE; Xu XH; Wang S
    Oncotarget; 2017 Feb; 8(8):13545-13559. PubMed ID: 28088790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chimeric Antigen receptor-T (CAR-T) cells targeting Epithelial cell adhesion molecule (EpCAM) can inhibit tumor growth in ovarian cancer mouse model.
    Fu J; Shang Y; Qian Z; Hou J; Yan F; Liu G; Dehua L; Tian X
    J Vet Med Sci; 2021 Mar; 83(2):241-247. PubMed ID: 33328392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Study on construction of c-Met specific CAR-T cells and its killing effect on non-small cell lung carcinoma].
    Min JT; Zhang L; Long CR; Fan HL; Li ZZ
    Zhonghua Zhong Liu Za Zhi; 2023 Apr; 45(4):322-329. PubMed ID: 37078213
    [No Abstract]   [Full Text] [Related]  

  • 8. Bispecific CAR T Cells against EpCAM and Inducible ICAM-1 Overcome Antigen Heterogeneity and Generate Superior Antitumor Responses.
    Yang Y; McCloskey JE; Yang H; Puc J; Alcaina Y; Vedvyas Y; Gomez Gallegos AA; Ortiz-Sánchez E; de Stanchina E; Min IM; von Hofe E; Jin MM
    Cancer Immunol Res; 2021 Oct; 9(10):1158-1174. PubMed ID: 34341066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chimeric antigen receptor T cell targeting EGFRvIII for metastatic lung cancer therapy.
    Zhang Z; Jiang J; Wu X; Zhang M; Luo D; Zhang R; Li S; He Y; Bian H; Chen Z
    Front Med; 2019 Feb; 13(1):57-68. PubMed ID: 30721445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-1 blockade does not improve efficacy of EpCAM-directed CAR T-cell in lung cancer brain metastasis.
    Blobner J; Dengler L; Eberle C; Herold JJ; Xu T; Beck A; Mühlbauer A; Müller KJ; Teske N; Karschnia P; van den Heuvel D; Schallerer F; Ishikawa-Ankerhold H; Thon N; Tonn JC; Subklewe M; Kobold S; Harter PN; Buchholz VR; von Baumgarten L
    Cancer Immunol Immunother; 2024 Oct; 73(12):255. PubMed ID: 39358663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetically Engineered CLDN18.2 CAR-T Cells Expressing Synthetic PD1/CD28 Fusion Receptors Produced Using a Lentiviral Vector.
    Lee HJ; Hwang SJ; Jeong EH; Chang MH
    J Microbiol; 2024 Jul; 62(7):555-568. PubMed ID: 38700775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Construction of a new anti-CD19 chimeric antigen receptor and the anti-leukemia function study of the transduced T cells.
    An N; Tao Z; Li S; Xing H; Tang K; Tian Z; Rao Q; Wang M; Wang J
    Oncotarget; 2016 Mar; 7(9):10638-49. PubMed ID: 26840021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of chimeric antigen receptor-modified T cells for the treatment of esophageal cancer.
    Yu F; Wang X; Shi H; Jiang M; Xu J; Sun M; Xu Q; Addai FP; Shi H; Gu J; Zhou Y; Liu L
    Tumori; 2021 Aug; 107(4):341-352. PubMed ID: 32988314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Bioinformatic prediction and validation of cellular-mesenchymal epithelial transition(c-Met) as a target for chimeric antigen receptor T (CAR-T) cell therapy in the treatment of colorectal cancer].
    Peng S; Min J; Long C; Xie Z; Zhang L; Li H; Li Z
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2024 Jul; 40(7):614-622. PubMed ID: 39179404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chimeric antigen receptor containing ICOS signaling domain mediates specific and efficient antitumor effect of T cells against EGFRvIII expressing glioma.
    Shen CJ; Yang YX; Han EQ; Cao N; Wang YF; Wang Y; Zhao YY; Zhao LM; Cui J; Gupta P; Wong AJ; Han SY
    J Hematol Oncol; 2013 May; 6():33. PubMed ID: 23656794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Construction of CD138-targeted chimeric antigen receptor- modified T cells and their effect in multiple myeloma therapy].
    Guo CC; Lu Y; Tang KJ; Xing HY; Tian Z; Rao Q; Wang M; Xiong DS; Wang JX
    Zhonghua Xue Ye Xue Za Zhi; 2024 May; 45(5):436-444. PubMed ID: 38964917
    [No Abstract]   [Full Text] [Related]  

  • 17. Adoptive T-cell therapy of prostate cancer targeting the cancer stem cell antigen EpCAM.
    Deng Z; Wu Y; Ma W; Zhang S; Zhang YQ
    BMC Immunol; 2015 Jan; 16(1):1. PubMed ID: 25636521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modification of cytokine-induced killer cells with folate receptor alpha (FRα)-specific chimeric antigen receptors enhances their antitumor immunity toward FRα-positive ovarian cancers.
    Zuo S; Wen Y; Panha H; Dai G; Wang L; Ren X; Fu K
    Mol Immunol; 2017 May; 85():293-304. PubMed ID: 28360017
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE), is highly active against primary uterine serous papillary carcinoma cell lines in vitro.
    Bellone S; Black J; English DP; Schwab CL; Lopez S; Cocco E; Bonazzoli E; Predolini F; Ferrari F; Ratner E; Silasi DA; Azodi M; Schwartz PE; Santin AD
    Am J Obstet Gynecol; 2016 Jan; 214(1):99.e1-8. PubMed ID: 26272866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PTK7-Targeting CAR T-Cells for the Treatment of Lung Cancer and Other Malignancies.
    Jie Y; Liu G; Feng L; Li Y; E M; Wu L; Li Y; Rong G; Li Y; Wei H; Gu A
    Front Immunol; 2021; 12():665970. PubMed ID: 34475869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.